A Review of Drug Therapy in the Management of Covid-19

A Review of Drug Therapy in the Management of Covid-19

Dinesh Dhodi

Contact

Dr. Amitrajit Pal

Contact

Maharashtra University of Health Sciences

A Review of Drug Therapy in the Management of Covid-19

Article Fingerprint

ReserarchID

PDDTMD1TDP

A Review of Drug Therapy in the Management of Covid-19 Banner

AI TAKEAWAY

Connecting with the Eternal Ground

Abstract

The wrath of the COVID-19 pandemic has crippled the entire world in a state of a medical emergency. The number of cases has been increasing at an alarming and exponential rate and exhausting the medical resources vastly, at the same time questioning the future of such a deadly pandemic. An amalgamation of medical and non-medical knowledge is being followed globally to flatten the curve. However, without any proven cure at hand, several drugs are being researched into studies like Favipiravir, Remdesivir, Tocilizumab, Hydroxychloroquine, to gain substantial evidence of their use either individually or in combination, supplemented by supportive therapy, vitamins, and zinc, to effectively treat the patients and curb the mortality rate of the population.

References

45 Cites in Article

Reference Format

Yudong Yin,Richard Wunderink (2018). MERS, SARS and other coronaviruses as causes of pneumonia.
(2020). Coronaviridae Study Group of the International Committee on Taxonomy of Viruses The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.
T Richard (2020). Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19.
Ali Zaki,Sander Van Boheemen,Theo Bestebroer,Albert Osterhaus,Ron Fouchier (2012). Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia.
A Walls,Y Park,M Tortorici (2020). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein.
Yousuke Furuta,Takashi Komeno,Takaaki Nakamura (2017). Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.
Vincent Madelain,Thi Nguyen,Anaelle Olivo,Xavier De Lamballerie,Jérémie Guedj,Anne-Marie Taburet,France Mentré (2016). Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.
Umang Agrawal,Reyma Raju,Zarir Udwadia (2020). Favipiravir: A new and emerging antiviral option in COVID-19.
E De Wit,F Feldmann,J Cronin (2020). Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
T Sheahan,A Sims,R Graham (2017). Broadspectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.
Timothy Sheahan,Amy Sims,Sarah Leist,Alexandra Schäfer,John Won,Ariane Brown,Stephanie Montgomery,Alison Hogg,Darius Babusis,Michael Clarke,Jamie Spahn,Laura Bauer,Scott Sellers,Danielle Porter,Joy Feng,Tomas Cihlar,Robert Jordan,Mark Denison,Ralph Baric (2020). Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.
Manli Wang,Ruiyuan Cao,Leike Zhang,Xinglou Yang,Jia Liu,Mingyue Xu,Zhengli Shi,Zhihong Hu,Wu Zhong,Gengfu Xiao (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Duxin Sun (2020). Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.
Neil Green,Robert D Ott,Richard J Isaacs,Hong Fang (2008). Cell-based assays to identify inhibitors of viral disease.
M Sheppard,F Laskou,P Stapleton,S Hadavi,B Dasgupta (2017). Tocilizumab (actemra).
Shengyu Zhang,Lei Li,Aizong Shen,Yongwu Chen,Zhigang Qi (2020). Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia.
Marcel Levi (2020). Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation.
Graeme Jones,Changhai Ding (2010). Tocilizumab: A Review of Its Safety and Efficacy in Rheumatoid Arthritis.
Yufang Shi,Ying Wang,Changshun Shao,Jianan Huang,Jianhe Gan,Xiaoping Huang,Enrico Bucci,Mauro Piacentini,Giuseppe Ippolito,Gerry Melino (2020). COVID-19 infection: the perspectives on immune responses.
Shu-Fen Wu,Chia-Bin Chang,Jui-Mei Hsu,Ming-Chi Lu,Ning-Sheng Lai,Chin Li,Chien-Hsueh Tung (2017). Hydroxychloroquine inhibits CD154 expression in CD4+ T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling.
Van Den Borne,Be,B Dijkmans,H De Rooij,S Le Cessie,C Verweij (1997). Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells.
V Lotteau,L Teyton,A Peleraux,T Nilsson,L Karlsson,S Schmid (1990). Intracellular transport of class II MHC molecules directed by invariant chain.
Tino Munster,John Gibbs,Danny Shen,Bruce Baethge,Gary Botstein,Jacques Caldwell,Fredrick Dietz,Robert Ettlinger,Harvey Golden,Herbert Lindsley,George Mclaughlin,Larry Moreland,W Roberts,Theodore Rooney,Bruce Rothschild,Marshall Sack,Anthony Sebba,Michael Weisman,Kathryn Welch,David Yocum,Daniel Furst (2002). Hydroxychloroquine concentration–response relationships in patients with rheumatoid arthritis.
A Makin,J Wendon,S Fitt,B Portmann,R Williams (1994). Fulminant hepatic failure secondary to hydroxychloroquine..
M Murphy,A Carmichael (2001). Fatal toxic epidermal necrolysis associated with hydroxychloroquine.
F Njoo,C Hack,J Oosting,L Luyendijk,J Stilma,A Kijlstra (1994). C-reactive protein and interleukin-6 are elevated in onchocerciasis patients after ivermectin treatment.
Dhyuti Gupta,Ajaya Sahoo,Alok Singh (2020). Ivermectin: potential candidate for the treatment of Covid 19.
Aránzazu González Canga,Ana Sahagún Prieto,M Diez Liébana,Nélida Fernández Martínez,Matilde Sierra Vega,Juan García Vieitez (2008). The Pharmacokinetics and Interactions of Ivermectin in Humans—A Mini-review.
(2020). Clinical Trials Registry-India Randomised controlled trial of ivermectin in hospitalised patients with COVID19.
Megan Brooks,Elena Burtseva,Philip Ellery,Glenn Marsh,Andrew Lew,Anatoly Slepushkin,Suzanne Crowe,Gregory Tannock (2012). Antiviral activity of arbidol, a broad‐spectrum drug for use against respiratory viruses, varies according to test conditions.
Zhenwei Wang,Xiaorong Chen,Yunfei Lu,Feifei Chen,Wei Zhang (2020). Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.
N Lian,H Xie,S Lin,J Huang,J Zhao,Q Lin (2020). Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study.
World Health Organization (2020). Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance.
W Alhazzani,M Moller,Y Arabi,M Loeb,M Gong,A Rhodes (2020). Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19).
Waleed Alhazzani,Morten Møller,Yaseen Arabi,Mark Loeb,Michelle Gong,Eddy Fan,Simon Oczkowski,Mitchell Levy,Lennie Derde,Amy Dzierba,Bin Du,Michael Aboodi,Hannah Wunsch,Maurizio Cecconi,Younsuck Koh,Daniel Chertow,Kathryn Maitland,Fayez Alshamsi,Emilie Belley-Cote,Massimiliano Greco,Matthew Laundy,Jill Morgan,Jozef Kesecioglu,Allison Mcgeer,Leonard Mermel,Manoj Mammen,Paul Alexander,Amy Arrington,John Centofanti,Giuseppe Citerio,Bandar Baw,Ziad Memish,Naomi Hammond,Frederick Hayden,Laura Evans,Andrew Rhodes (2020). Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19).
J Zaroob,D Cender (1998). A different look at corticosteroids.
A Singh,S Majumdar,R Singh,A Misra (2020). Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective.
B Bikdeli,M Madhavan,D Jimenez,T Chuich,I Dreyfus,E Driggin (2020). COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up.
Ling Lin,Lianfeng Lu,Wei Cao,Taisheng Li (2020). Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia.
Klaus-Helge Ibs,Lothar Rink (2003). Zinc-Altered Immune function.
Silke Overbeck,Lothar Rink,Hajo Haase (2008). Modulating the immune response by oral zinc supplementation: a single approach for multiple diseases.
(2020). Reducing Dietary Salt to Improve Health in the Americas: Fact Sheet for Healthcare Professionals.
Y Zhou,B Luo,L Qin (2019). The association between vitamin D deficiency and communityacquired pneumonia: A meta-analysis of observational studies.
H Hemilä,E Chalker (2019). Vitamin C can shorten the length of stay in the ICU: a metaanalysis.
Fengming Huang,Cong Zhang,Qiang Liu,Yan Zhao,Yuqing Zhang,Yuhao Qin,Xiao Li,Chang Li,Congzhao Zhou,Ningyi Jin,Chengyu Jiang (2020). Identification of amitriptyline HCl, flavin adenine dinucleotide, azacitidine and calcitriol as repurposing drugs for influenza A H5N1 virus-induced lung injury.

Download References

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Dinesh Dhodi. 2020. \u201cA Review of Drug Therapy in the Management of Covid-19\u201d. Global Journal of Medical Research - B: Pharma, Drug Discovery, Toxicology & Medicine GJMR-B Volume 20 (GJMR Volume 20 Issue B8).

More Citation Formats

Select Citation Style:

Download Citation

GJMR Volume 20 Issue B8

Explore Journals Explore Volume Read This Issue

Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords

Not Found

Classification

GJMR-B Classification NLMC Code: WB 330

Submission ReceivedDecember 9, 2019
Peer Review Double Blind
Handling Editor
Accepted January 2, 2020
Published January 15, 2020

Version of record

v1.2

Issue date

December 10, 2020

Language

Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

View in VR

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

View in 3D

Article Matrices

Total Views: 2206

Total Downloads: 1027

2026 Trends

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]